BREAST CANCER

Across 3 HER2-negative biomarker signature groups, treatment with intra-tumoral SD-101 in combination with pembrolizumab and paclitaxel increased estimated pathological complete response rates in patients with high-risk, HER2-negative stage II/III breast cancer, but the results were not considered significant, according to findings from the phase 2 I-SPY 2 trial.

Investigators in the PALOMA-3 trial have concluded that Palbociclib plus fulvestrant maintains a clinically meaningful long-term overall survival benefit for patients with either HR+ or HER2 negative breast cancer.

Patients with early-stage breast cancer who have ultralow risk disease, indicated by a 70-gene signature, demonstrated an excellent survival prognosis regardless of clinical risk.

New results, presented at the 2021 ASCO annual meeting, show the benefit of adding durvalumab to neoadjuvant anthracycline and taxane–based chemotherapy for patients with early triple-negative breast cancer.

Overall survival in postmenopausal patients with hormone receptor–positive, HER2-negative advanced breast cancer at almost 5 years of follow-up continued to improve with Ribociclib plus fulvestrant over fulvestrant alone, irrespective of whether patients received the regimen in the first- or second-line setting.

Compared to fulvestrant alone, venetoclax and fulvestrant did not improve overall outcomes in patients with locally advanced or metastatic estrogen receptor–positive, HER2-negative breast cancer who had previously received a CDK4/6 inhibitor.

The FDA has accepted the biologics license application for peg-filgrastim, a proposed pegfilgrastim biosimilar.

Carey Anders, MD, presents a case that focuses on a patient with HER2+ breast cancer and brain metastases.

Experts in the field of breast cancer review the place in therapy for margetuximab.

Experts in the management of breast cancer review clinical trial data using PARP inhibitors in the treatment of BRCA1/2-mutated TNBC.

The panel of experts in breast cancer discusses the treatment options for a patient with systemic progression of HER2+ disease on T-DM1 and no CNS metastases.

Experts in the management of breast cancer discuss the role of tucatinib in patients with brain metastases.

Experts in the management of breast cancer review some treatment considerations surrounding the use of PARP inhibitors in BRCA1/2–positive triple-negative breast cancer.

Elizabeth Mittendorf, MD, PhD, presents the case of a 34-year-old woman with PD-L1–positive triple-negative breast cancer.

The panel discusses treatment options and considerations for a 53-year-old woman with PD-L1+ triple-negative breast cancer.

Carey Anders, MD, and Andrew Seidman, MD, share their recommendations for HER2+ breast cancer recurrence within 12 months of HP.

The panel of experts review the study design and key efficacy data of the KEYNOTE-355 trial.

The panel of experts in breast cancer discuss treatment options when the cancer has metastasized.

Experts in breast cancer discuss efficacy data from the IMpassion130 clinical trial.

Elizabeth Mittendorf, MD, PhD, reviews the case of a 53-year-old woman with PD-L1+ TNBC breast cancer and the panel discusses relevant clinical trial data.

Ingrid Mayer, MD, MSCI, presents the case of a patient with high-risk HR+/HER2+ breast cancer who develops recurrence after a long disease-free interval.

The investigational CDK4/6 ARK5 inhibitor, ON 123300, has been dosed in the first time in a patient whose is enrolled in a phase 1 trial of ON 123300 for the treatment of advanced cancers.

Nadia Harbeck, MD, PhD, discusses how the monarchE trial, which evaluated the efficacy of endocrine therapy with or without abemaciclib, will change breast cancer treatment.

Experts in the management of breast cancer review some trials leading to the future of personalized treatment for HER2+ breast cancer.

Andrew Seidman, MD, follows the patient after TCHP therapy and discusses the risk of recurrence with the experts.